Healthcare products company CCA Industries Inc (OTC:CAWW) disclosed on Monday that its income amounted to USD349,320 for the second quarter ended 31 May 2019.
This marks an improvement when compared with a loss of USD292,320 for the same period in fiscal 2018.
Revenues of USD5.458m were generated for the three months ended 31 May 2019,up over revenues of USD4.225m for the comparable period in fiscal 2018.
EBITDA of USD574,176 were recorded for the second quarter ended 31 May 2019, a rise from EBITDA of USD231,136 for the corresponding period in fiscal 2018.
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation